Evidence map›Paper›PMID 40536312›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2025

Synergistic optimizations of efficacy and membrane permeability of IRAK4 inhibitors: identifying new lead compounds for anti-inflammatory therapeutics.

Kewon Kim, Ahyoung Jang, Hyeonsoo Han, Taeho Kim, Hwangseo Park, Sungwoo Hong

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kewon KimDepartment of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.
Ahyoung JangDepartment of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.
Hyeonsoo HanDepartment of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.
Taeho KimDepartment of Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Hwangseo ParkDepartment of Bioscience and Biotechnology, Sejong University, Seoul, Korea.
Sungwoo HongDepartment of Chemistry, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interleukin-1 receptor-associated kinase 4 (IRAK4) is a serine/threonine kinase that plays a pivotal role in immune signalling and cytokine regulation, making it a compelling target for the treatment of inflammatory and autoimmune diseases. We initiated a drug discovery campaign based on the

Indexed as

Anti-Inflammatory Agents, Non-SteroidalCell Membrane PermeabilityInterleukin-1 Receptor-Associated KinasesProtein Kinase InhibitorsPyrimidinesDose-Response Relationship, DrugHumansMolecular StructureQuantitative Structure-Activity RelationshipAnti-Inflammatory Agents, Non-SteroidalInterleukin-1 Receptor-Associated KinasesIRAK4 protein, humanProtein Kinase InhibitorsPyrimidines3D-QSARde novo designIRAK4 inhibitorkinasemembrane permeability

Identifiers

PMID40536312
PMCPMC12180326

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.